AI’s Role in Prior Authorization: A Double-Edged Sword for Healthcare Access and Efficiency
The United States government is currently piloting a program that leverages artificial intelligence (AI) to inform insurance-coverage decisions, aiming to streamline processes and reduce unnecessary medical spending. This initiative comes amidst a long-standing national debate over prior authorization, a practice designed to control healthcare costs but widely criticized for creating significant delays and denials of medically necessary care. While AI offers the theoretical promise of expedited claims, its implementation is already facing considerable resistance and scrutiny due to concerns about increased wrongful denials and a potential exacerbation of an already tortuous system.
The Intricacies of Prior Authorization: A System Under Fire
For many Americans, the process of obtaining pre-approval for physician-recommended medical care is a familiar and often frustrating ordeal. Personal accounts frequently highlight the tribulations patients endure, navigating complex bureaucratic hurdles to secure insurer payment for prescription medications, medical procedures, and other vital services. This system, known as prior authorization, serves as a mechanism for health insurers to verify eligibility and medical necessity before approving treatments. Its stated purpose is to act as a check on healthcare overuse and spending, ensuring that patients receive appropriate care and that less costly alternatives are considered when viable.
However, the efficacy and fairness of prior authorization have been consistently questioned. A significant majority of physicians, as evidenced by various surveys, voice profound concerns about care delays. These delays can lead to adverse outcomes, including patients abandoning recommended treatments while awaiting insurer verification. When care is denied, patients are often forced to undertake a time-consuming appeal process, adding further stress and potential health deterioration. The American Medical Association (AMA) has been a vocal advocate for reform, highlighting that these delays and denials frequently cause patients to forgo necessary treatments.
The AI Promise: Efficiency and Expedited Approvals
The advent of artificial intelligence presents a seemingly attractive solution to the administrative burden and delays associated with prior authorization. With its unparalleled ability to efficiently sort through vast quantities of information, AI could theoretically expedite the approval of unambiguously allowable claims. By automating the review of routine cases and quickly identifying treatments that clearly meet established medical criteria, AI systems could reduce the need for manual review, thereby potentially cutting down on administrative waste and accelerating patient access to care. Proponents suggest that AI could free up human reviewers to focus on more complex or nuanced cases, leading to a more efficient and responsive system overall.
The AI Peril: Concerns Over Increased Denials and Lack of Transparency
Despite the allure of efficiency, the integration of AI into prior authorization is confronting significant resistance, largely stemming from fears that it could lead to an increase in wrongful denials of health insurance coverage. A 2025 survey conducted by the American Medical Association revealed widespread physician apprehension, with 61 percent of doctors expressing worry that AI would exacerbate denials of what they consider necessary treatments. This concern is not unfounded, as AI algorithms, if not meticulously designed and rigorously overseen, can perpetuate biases present in their training data or be optimized for cost savings over patient care.
Health policy analysts like Camm Epstein articulate a critical principle: "AI should be used to make appropriate care easier to approve, not necessary care easier to deny." This sentiment underscores a fundamental ethical dilemma when deploying AI in sensitive areas like healthcare. Critics demand greater transparency regarding the underlying algorithms that drive AI-powered authorization decisions. The AMA advocates for requiring insurers to provide detailed clinical reasoning to justify any denials of coverage, emphasizing that the "black box" nature of some AI systems is unacceptable when patient health is at stake. Without clear explanations, patients and providers are left without recourse or understanding of why critical care might be withheld.
The Current Landscape: Government Initiatives and Industry Pledges
The current administration has been actively engaged in efforts to reform prior authorization, albeit with what appears to be a bifurcated approach.
In 2024, the former President Joe Biden’s administration issued a significant rule aimed at reducing delays for patients covered by government-run plans and streamlining the prior authorization process for physicians. This regulation mandated that insurers make certain prior authorization decisions within 72 hours for urgent requests and seven calendar days for non-urgent requests. These critical timeline requirements officially went into effect on January 1st of this year for most public-sector health plans, representing a concrete step toward improving patient access and reducing prolonged waiting periods.
Concurrently, the Trump administration has pursued its own initiatives. Last year, in collaboration with major insurers, the administration pledged to further streamline and accelerate prior authorization processes. Private insurance companies, in response to growing pressure, vowed to standardize electronic requests by 2027 and committed to reducing the volume of medical services subject to prior authorization by 2026. This includes common procedures such as colonoscopies and cataract surgeries, signaling an intent to ease the burden for frequently approved treatments.
However, a new and potentially controversial development under the Trump administration is the piloting of a program called WISeR, or Wasteful and Inappropriate Service Reduction Model. Launched this year by the Centers for Medicare and Medicaid Services (CMS), WISeR is a demonstration project designed to reduce waste and fraud specifically within original Medicare. The model, which runs through December 2031 across six states, integrates advanced technologies like machine learning with human clinical review. It targets services CMS identifies as potentially vulnerable to overuse, fraud, and abuse, including skin and tissue substitutes, electrical nerve stimulator implants, and knee arthroscopy for knee osteoarthritis.
This expansion of prior authorization into original Medicare, a domain where it has historically been sparingly used, marks a significant shift. Critics express concern that this move could negatively impact patient access, drawing parallels to challenges observed in Medicare Advantage.
The Impact on Patients: Delays, Denials, and Deteriorating Health
Regardless of the degree to which AI is involved, the public consistently views prior authorization as a major burden. This is particularly evident in Medicare Advantage (MA), the privately run alternative to original Medicare, which now covers approximately 55 percent of Medicare-eligible seniors and disabled individuals. Insurers in MA issue millions of full or partial claim denials annually based on prior authorization. Federal government reports, including memoranda from the HHS Office of Inspector General (OIG) in 2022 and 2026, have highlighted troubling patterns. The 2022 OIG report, for instance, pointed to more than one in ten instances where MA plans denied beneficiaries access to services despite their apparent fulfillment of coverage rules. While MA plans reportedly overturned 81 percent of denials upon appeal in 2024, this high overturn rate underscores the initial erroneous denials and the significant administrative and emotional burden placed on patients and providers to appeal. The 2026 OIG reports further documented instances where large MA organizations denied requests for long-term acute care and inpatient rehabilitation at alarmingly high rates, raising serious concerns about obstacles to medically appropriate care.
The human cost of these delays and denials is substantial. An NBC News report vividly described some patients as being "stuck in prior authorization purgatory," running out of time or treatment options while awaiting approvals. A newly released Commonwealth Fund survey in June 2026 painted a stark picture, revealing that roughly one in five American working-age adults with private insurance reported that they or a family member were denied insurance coverage for physician-recommended medical care in 2025. Of those who experienced a prior authorization denial, 41 percent said it delayed their care, and more than a quarter reported that their health problem worsened as a direct result. These statistics underscore the critical need for a system that prioritizes patient well-being over administrative hurdles.
The Profit Motive and Political Pushback
A central point of contention surrounding the WISeR model is its financial structure. Vendors participating in the program, hired to carry out AI-driven prior authorization, earn a share of what CMS terms "averted expenditures." This arrangement raises a profound ethical question: does it create a financial incentive for vendors to reject care requests, thereby prioritizing cost savings over patient needs? This concern ties into a broader, long-standing debate about profit-making within the healthcare system, particularly when it appears to be predicated on discouraging patients from receiving medically necessary care.
The WISeR model has already garnered significant political pushback. Wendell Potter, a prominent advocate for health insurance reform and former executive at Cigna, has extensively covered the political opposition to the model. Similarly, Zena Wolf, a researcher with the Center for Health & Democracy, cited investigations by leading news outlets suggesting that in its initial months, the WISeR model has indeed caused care delays and denials in some instances across the six pilot states. Lawmakers, echoing these concerns, have introduced resolutions and amendments to block funding for the WISeR model, citing direct threats to patient access.
Official Responses and Future Outlook
Amidst this complex landscape, CMS Administrator Mehmet Oz has issued a clear warning to insurance company executives: ease the burden of prior authorization or face federal regulation. "If you don’t do it yourselves, then we’re going to do it for you," he stated, signaling a potential for more stringent government oversight if industry-led reforms fall short.
In what may be an attempt to preempt further executive action or legislative intervention, health plans recently released data suggesting compliance with administration demands. An industry-based survey revealed an 11 percent decline in prior authorization requests between June 2025 and April 2026. This data also highlighted pledges to support continuity of care and enhanced consumer communications. However, critical questions remain, particularly whether the denial rate has actually decreased, a point that health policy experts at KFF have noted is still unknown.
In a separate industry survey conducted last year, all responding health plans affirmed that "AI or algorithms without clinician or practitioner review are not used to deny prior authorization requests that involve medical necessity or clinical considerations." Insurers also promised greater transparency regarding the clinical reasoning underpinning their prior authorization decisions. These assurances aim to alleviate concerns about a lack of human oversight in AI-driven decisions, yet placating detractors remains a significant challenge.
Jared Dashevsky, a physician and founder of Healthcare Huddle, encapsulates the skepticism: "AI could eliminate barriers, reduce administrative waste, give us more time with patients. But that’s not what’s being built." Instead, he argues, the current trajectory seems to be an "arms race to deny faster and appeal faster," representing "more automation of a broken system that shouldn’t exist in its current form."
The integration of AI into prior authorization represents a critical juncture for the U.S. healthcare system. While the technology holds undeniable potential for efficiency gains, its deployment must be guided by robust ethical frameworks, stringent oversight, and a steadfast commitment to patient welfare. The ongoing debate underscores the fundamental tension between cost containment and ensuring timely access to medically necessary care, a balance that AI, if not carefully managed, could further destabilize. The success of these initiatives will ultimately hinge on whether they genuinely serve to improve patient outcomes and alleviate the burdens on providers, rather than merely automating and accelerating a system already fraught with challenges.
